KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAmortization of GoodwillAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Baxter International (BAX) Gains from Sales and Divestitures (2010 - 2018)

Baxter International (BAX) reported Gains from Sales and Divestitures of $1.0 million for Q4 2018, up 428.35% year-over-year from $194000.0 in Q4 2017, and up 428.35% on a QoQ basis from $194000.0 in Q4 2017.

Baxter International (BAX) has 9 years of Gains from Sales and Divestitures data on file, last reported at $1.0 million in Q4 2018.

  • Quarterly Gains from Sales and Divestitures rose 428.35% year-over-year to $1.0 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $1.0 million (up 428.35% YoY) and the FY2018 annual result came in at $1.0 million, up 428.35% from the prior year.
  • Gains from Sales and Divestitures advanced to $1.0 million in Q4 2018 per BAX's latest filing, from $194000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.3 million in Q4 2016 and bottomed at $194000.0 in Q4 2017.
  • The 5-year median for Gains from Sales and Divestitures is $1.0 million (2018), against an average of $778400.0.
  • The widest annual swing landed in 2017, when Gains from Sales and Divestitures slumped 84.74%; it then surged 428.35% in 2018.
  • Tracing BAX's Gains from Sales and Divestitures over 5 years: stood at $360000.0 in 2014, then jumped by 189.44% to $1.0 million in 2015, then increased by 21.98% to $1.3 million in 2016, then tumbled by 84.74% to $194000.0 in 2017, then surged by 428.35% to $1.0 million in 2018.
  • Per Business Quant, the three latest BAX Gains from Sales and Divestitures figures stand at $1.0 million (Q4 2018), $194000.0 (Q4 2017), and $1.3 million (Q4 2016).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Repligen 6.39 Bn 5.41 Bn 108.28 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2018 1.03 Mn
Dec 31, 2018 1.03 Mn
Dec 31, 2017 194,000.00
Dec 31, 2017 194,000.00
Dec 31, 2016 1.27 Mn
Dec 31, 2016 1.27 Mn
Dec 31, 2015 1.04 Mn
Dec 31, 2015 1.04 Mn
Dec 31, 2014 360,000.00
Dec 31, 2014 360,000.00
Dec 31, 2013 387,000.00
Dec 31, 2013 387,000.00
Dec 31, 2012 348,000.00
Dec 31, 2012 348,000.00
Dec 31, 2011 409,000.00
Dec 31, 2011 409,000.00
Dec 31, 2010 -168,000.00
Dec 31, 2010 -168,000.00